Recent Updates — ALPS

Alps Group Inc is seeking shareholder approval at an extraordinary general meeting on October 21, 2026, for a proposed 1-for-5 reverse stock consolidation of its Ordinary and Preferred Shares. The move aims to comply with Nasdaq's minimum bid price listing requirements. Additionally, the company proposes increasing its authorized share capital from US$50,000 to US$105,000, creating 210 million shares. These changes require adoption of a second amended and restated memorandum and articles of association. Alps Group Inc operates in the investment holding sector.

Alps Group Inc announced on June 23, 2026, the launch of a patient-derived organoid program to advance personalized cancer care in Southeast Asia. The company operates in the healthcare sector and provides personalized cancer care solutions.

On June 9, 2026, Alps Group Inc announced that its subsidiary, MyGenome Sdn. Bhd., received accreditation for Whole Genome Sequencing under MS ISO 15189:2022. The company operates in the healthcare industry, providing genomic testing and diagnostic services.